Prognosis of hepatocellular carcinoma expressing cytokeratin 19: Comparison with other liver cancers

被引:58
作者
Lee, Jung Il [1 ]
Lee, Jin-Woo
Kim, Joon Mee [2 ]
Kim, Ja Kyung [3 ]
Chung, Hyun Jung [3 ]
Kim, Young Soo
机构
[1] Inha Univ, Sch Med, Div Gastroenterol & Hepatol, Dept Internal Med, Inchon 400711, South Korea
[2] Inha Univ, Sch Med, Dept Pathol, Inchon 400711, South Korea
[3] Yonsei Univ, Coll Med, Dept Internal Med, Gangnam Severance Hosp, Seoul 135720, South Korea
关键词
Cytokeratin; 19; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; Liver cancers; Hepatectomy; GROWTH-FACTOR RECEPTOR; CHOLANGIOCARCINOMA; CLASSIFICATION; MODEL;
D O I
10.3748/wjg.v18.i34.4751
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate whether expressing biliary phenotype predicted poor outcome after the surgical treatment in primary liver cancers. METHODS: Out of 204 patients that underwent liver resection due to hepatocellular carcinoma (HCC), liver specimens of 70 patients with HCC were evaluated for biliary components by cytokeratin (CK) 19 immunostain (CK19(-) HCC and CK19(+) HCC). CK19 positivity was defined as membranous and/or cytoplasmic expression in >= 5% of tumor cells with moderate or strong intensity. Patients with other primary liver cancers, such as combined HCC and cholangiocarcinoma (cHCC-CC), intrahepatic cholangiocarcinoma (ICC) who received curative liver resection, were also included in the study. Clinical characteristics of CK19- HCC and CK19+ HCC patients, including survival outcome after curative liver resection, were compared with that of cHCC-CC and ICC patients. RESULTS: The overall survival (OS) rate of CK19(-) HCC (n = 49) after the curative surgical treatment was 90.7%, and 80.4% at 1 and 5 years after the resection. OS rate of CK19(+) HCC (n = 21) was 74.3%, 28.9% and OS rate of cHCC-CC (n = 22) was 66.7%, 32.2% at 1 and 5 years after the surgery. For ICC (n = 19), 1 and 5-year-OS rate was 50.2% and 14.3% after the curative resection. The OS rates of CK19(+) HCC and cHCC-CC were significantly lower than that of CK19(-) HCC, but higher than the OS rate of ICC (P = 0.000). There was no statistically significant difference in OS rate between CK19(+) HCC and cHCC-CC. The disease free survival (DFS) rate of CK19(-) HCC was 72.0% and 54.5% at 1 and 3 years after the surgical treatment. DFS rate of CK19(+) HCC was 53.3%, 34.3% and DFS rate of cHCC-CC was 51.5%, 39.2% at 1 and 3 years after the resection. For ICC, 1 and 3-year-DFS rate was 28.0% and 14.0% after the curative resection. DFS rate of CK19(-) HCC was significantly higher than that of ICC (P = 0.017), but marginally higher than DFS rate of either CK19(+) HCC or cHCC-CC (P = 0.097, P = 0.089, respectively). Predictors of outcome after the surgery of primary liver cancer were pathology of the resected mass, existence of microvascular invasion and accompanying satellite nodule. CONCLUSION: Primary liver cancers with biliary components tended to show poorer surgical outcome. This suggested that immuno-phenotype of liver cancers was as important as their morphological classification. (C) 2012 Baishideng. All rights reserved.
引用
收藏
页码:4751 / 4757
页数:7
相关论文
共 27 条
  • [1] Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation - Subdivision and comparison with ordinary hepatocellular carcinoma
    Aishima, Shinichi
    Nishihara, Yunosuke
    Kuroda, Yousuke
    Taguchi, Kenichi
    Iguchi, Tomohiro
    Taketomi, Akinobu
    Maehara, Yoshihiko
    Tsuneyoshi, Masazumi
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2007, 31 (05) : 783 - 791
  • [2] Progenitor-Derived Hepatocellular Carcinoma Model in the Rat
    Andersen, Jesper B.
    Loi, Roberto
    Perra, Andrea
    Factor, Valentina M.
    Ledda-Columbano, Giovanna M.
    Columbano, Amedeo
    Thorgeirsson, Snorri S.
    [J]. HEPATOLOGY, 2010, 51 (04) : 1401 - 1409
  • [3] [Anonymous], 2010, WHO Classification of tumors of the digestive system
  • [4] Combined Hepatocellular-Cholangiocarcinoma Had Poor Outcomes after Hepatectomy Regardless of Allen and Lisa Class or the Predominance of Intrahepatic Cholangiocarcinoma Cells within the Tumor
    Ariizumi, Shun-ichi
    Kotera, Yoshihito
    Katagiri, Satoshi
    Nakano, Masayuki
    Yamamoto, Masakazu
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (05) : 1628 - 1636
  • [5] Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets
    Boyault, Sandrine
    Rickman, David S.
    de Reynies, Aurelien
    Balabaud, Charles
    Rebouissou, Sandra
    Jeannot, Emmanuelle
    Herault, Aurelie
    Saric, Jean
    Belghiti, Jacques
    Franco, Dominique
    Bioulac-Sage, Paulette
    Laurent-Puig, Pierre
    Zucman-Rossi, Jessica
    [J]. HEPATOLOGY, 2007, 45 (01) : 42 - 52
  • [6] Cai X, 2012, HEPATOLOGY
  • [7] The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin
    Durnez, A.
    Verslype, C.
    Nevens, F.
    Fevery, J.
    Aerts, R.
    Pirenne, J.
    Lesaffre, E.
    Libbrecht, L.
    Desmet, V.
    Roskams, T.
    [J]. HISTOPATHOLOGY, 2006, 49 (02) : 138 - 151
  • [8] Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects
    Forner, Alejandro
    Reig, Maria E.
    Rodriguez de Lope, Carlos
    Bruix, Jordi
    [J]. SEMINARS IN LIVER DISEASE, 2010, 30 (01) : 61 - 74
  • [9] Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma
    Höpfner, M
    Sutter, AP
    Huether, A
    Schuppan, D
    Zeitz, M
    Scherübl, H
    [J]. JOURNAL OF HEPATOLOGY, 2004, 41 (06) : 1008 - 1016
  • [10] Combined hepatocellular and cholangiocarcinoma - Demographic, clinical, and prognostic factors
    Jarnagin, WR
    Weber, S
    Tickoo, SK
    Koea, JB
    Obiekwe, S
    Fong, YM
    DeMatteo, RP
    Blumgart, LH
    Klimstra, D
    [J]. CANCER, 2002, 94 (07) : 2040 - 2046